NNC0487-0111 and the body's energy use after weight loss in overweight or obesity
Tests how NNC0487-0111 changes energy use after weight loss in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo
Key facts
- Where
- Aarhus N, DenmarkSee the site
- Phase
- Phase 1
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07757087EU 2025-522744-40-00
- Record updated
- 1 October 2026
- Original description
The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).Read full original descriptionShow less
The Effect of Once-weekly Subcutaneous NNC0487-0111 Compared to an Energy-restricted Diet or Placebo on Energy Metabolism in Adults Living With Overweight or Obesity: a Randomised, Placebo-controlled Study
The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity or overweight following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or older at the time of signing the informed consent.
Exclusion: Use of any weight lowering pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilisers 6 months prior to screening; Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issue; Physical activity of moderate to vigorous intensity for greater than (>) 4 hours/week within the past 6 months before screening; Any condition, or disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol; History of type 1 or type 2 diabetes mellitus; Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal (GI), or endocrinological conditions; Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study; Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method; Exposure to an investigational medicinal product within 30 days; Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study, for example, an imminent job change to/from a physically demanding occupation; Claustrophobia or severe discomfort of being confined in small rooms.